Abstract
The posterior pituitary is comprised of the end terminals of specialized hypothalamic neurons called neurohypophyseal neurons. The two hormones of the posterior pituitary, arginine vasopressin (AVP) and oxytocin (OT), are synthesized in the cell bodies of the neurohypophyseal neurons. The pre-prohormones are cleaved from the signal peptide in the endoplasmic reticulum, and the prohormones, provasopressin and pro-oxytocin, are packaged along with processing enzymes into neurosecretory granules. The neurosecretory granules are transported out of the perikaryon of the neurohypophyseal neurons via microtubules down the long axons that form the supraopticohypophyseal tract to terminate in axon terminals in the posterior pituitary. The entire unit including the magnocellular neurons in the SON and PVN, the supraopticohypophyseal tract, and the axon terminals in the posterior pituitary is called the neurohypophysis. The primary physiologic action of AVP is its function as a water-retaining hormone via activation of vasopressin V2 receptors in the principal cells of the kidney collecting duct. Disorders of AVP synthesis or secretion can lead to excessive water excretion (diabetes insipidus) or inappropriate water retention (syndrome of inappropriate antidiuretic hormone secretion). The primary physiologic action of OT is its function to stimulate milk secretion during suckling via activation of OT receptors in the breast with subsequent contraction of myoepithelial cells around the breast alveoli and ductules to eject milk. Disorders of OT synthesis or secretion can lead to inability to eject breast milk postpartum, though clinical cases have not been described in humans. Both AVP and OT are also synthesized in parvocellular hypothalamic neurons that project within the brain and regulate a variety of central nervous system functions, not all of which have been characterized.
References
Adrogue HJ, Madias NE. Hypernatremia. N Engl J Med. 2000a;342(20):1493–9. Available from: PM:10816188.
Adrogue HJ, Madias NE. Hyponatremia. N Engl J Med. 2000b;342(21):1581–9. Available from: PM:0010824078.
Ayus JC. Diuretic-induced hyponatremia [editorial]. Arch Intern Med. 1986;146(7):1295–6. Available from: PM:0003718124.
Babey M, Kopp P, Robertson GL. Familial forms of diabetes insipidus: clinical and molecular characteristics. Nat Rev Endocrinol. 2011;7(12):701–14. Available from: PM:21727914.
Bartter FC, Schwartz WB. The syndrome of inappropriate secretion of antidiuretic hormone. Am J Med. 1967;42:790–806.
Battison C, Andrews PJ, Graham C, Petty T. Randomized, controlled trial on the effect of a 20% mannitol solution and a 7.5% saline/6% dextran solution on increased intracranial pressure after brain injury. Crit Care Med. 2005;33(1):196–202. Available from: PM:15644669.
Baylis PH, Thompson CJ. Osmoregulation of vasopressin secretion and thirst in health and disease. Clin Endocrinol (Oxf). 1988;29(5):549–76. Available from: PM:3075528.
Baylis PH, Thompson CJ. Diabetes insipidus and hyperosmolar syndromes. In: Becker KL, editor. Principles and practice of endocrinology and metabolism. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 285–93.
Berl T. Impact of solute intake on urine flow and water excretion. J Am Soc Nephrol. 2008;19(6):1076–8. Available from: PM:18337482.
Berl T, Quittnat-Pelletier F, Verbalis JG, Schrier RW, Bichet DG, Ouyang J, Czerwiec FS. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol. 2010;21(4):705–12. Available from: PM:20185637.
Bissram M, Scott FD, Liu L, Rosner MH. Risk factors for symptomatic hyponatraemia: the role of pre-existing asymptomatic hyponatraemia. Intern Med J. 2007;37(3):149–55. Available from: PM:17316332.
Decaux G. The syndrome of inappropriate secretion of antidiuretic hormone (SIADH). Semin Nephrol. 2009;29(3):239–56. Available from: PM:19523572.
Decaux G, Genette F. Urea for long-term treatment of syndrome of inappropriate secretion of antidiuretic hormone. Br Med J – Clin Res. 1981;283:1081–3.
Decaux G, Waterlot Y, Genette F, Mockel J. Treatment of the syndrome of inappropriate secretion of antidiuretic hormone with furosemide. N Engl J Med. 1981;304:329–30.
Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med. 2007;356(20):2064–72. Available from: PM:17507705.
Fujiwara TM, Bichet DG. Molecular biology of hereditary diabetes insipidus. J Am Soc Nephrol. 2005;16:2836. Available from: PM:16093448.
Furst H, Hallows KR, Post J, Chen S, Kotzker W, Goldfarb S, Ziyadeh FN, Neilson EG. The urine/plasma electrolyte ratio: a predictive guide to water restriction. Am J Med Sci. 2000;319(4):240–4. Available from: PM:0010768609.
Goldszmidt MA, Iliescu EA. DDAVP to prevent rapid correction in hyponatremia. Clin Nephrol. 2000;53(3):226–9. Available from: PM:0010749304.
Greenberg A, Verbalis JG. Vasopressin receptor antagonists. Kidney Int. 2006;69(12):2124–30. Available from: PM:16672911.
Grunfeld JP, Rossier BC. Lithium nephrotoxicity revisited. Nat Rev Nephrol. 2009;5(5):270–6. Available from: PM:19384328.
Gullans SR, Verbalis JG. Control of brain volume during hyperosmolar and hypoosmolar conditions. Annu Rev Med. 1993;44:289–301.
Heinbecker P, White HL. Hypothalamico-hypophyseal system and its relation to water balance in the dog. Am J Physiol. 1941;133:582–93.
Hew-Butler T, Ayus JC, Kipps C, Maughan RJ, Mettler S, Meeuwisse WH, Page AJ, Reid SA, Rehrer NJ, Roberts WO, Rogers IR, Rosner MH, Siegel AJ, Speedy DB, Stuempfle KJ, Verbalis JG, Weschler LB, Wharam P. Statement of the second international exercise-associated hyponatremia consensus development conference, New Zealand, 2007. Clin J Sport Med. 2008;18(2):111–21. Available from: PM:18332684.
Ishikawa S, Fujita N, Fujisawa G, Tsuboi Y, Sakuma N, Okada K, Saito T. Involvement of arginine vasopressin and renal sodium handling in pathogenesis of hyponatremia in elderly patients. Endocr J. 1996;43(1):101–8.
Johnson AK, Buggy J. Periventricular preoptic-hypothalamus is vital for thirst and normal water economy. Am J Physiol. 1978;234(3):R122–9. Available from: PM:629368.
Khanna A. Acquired nephrogenic diabetes insipidus. Semin Nephrol. 2006;26(3):244–8. Available from: PM:16713497.
Li-Ng M, Verbalis JG. Conivaptan: evidence supporting its therapeutic use in hyponatremia. Core Evid. 2010;4:83–92. Available from: PM:20694067.
Morgenthaler NG, Struck J, Jochberger S, Dunser MW. Copeptin: clinical use of a new biomarker. Trends Endocrinol Metab. 2008;19(2):43–9. Available from: PM:18291667.
Oelkers W. Hyponatremia and inappropriate secretion of vasopressin (antidiuretic hormone) in patients with hypopituitarism. N Engl J Med. 1989;321:492–6.
Ohnishi A, Orita Y, Okahara R, Fujihara H, Inoue T, Yamamura Y, Yabuuchi Y, Tanaka T. Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men. J Clin Invest. 1993;92(6):2653–9. Available from: PM:8254021.
Oya S, Tsutsumi K, Ueki K, Kirino T. Reinduction of hyponatremia to treat central pontine myelinolysis. Neurology. 2001;57(10):1931–2. Available from: PM:11723299.
Renneboog B, Musch W, Vandemergel X, Manto MU, Decaux G. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med. 2006;119(1):71. Available from: PM:16431193.
Robertson GL. Diabetes insipidus. Endocrinol Metab Clin North Am. 1995;24(3):549–72. Available from: PM:0008575409.
Robertson GL. Regulation of arginine vasopressin in the syndrome of inappropriate antidiuresis. Am J Med. 2006;119(7 Suppl 1):S36–42. Available from: PM:16843083.
Robinson AG. DDAVP in the treatment of central diabetes insipidus. N Engl J Med. 1976;294(10):507–11. Available from: PM:1250255.
Robinson AG. Disorders of antidiuretic hormone secretion. J Clin Endocrinol Metab. 1985;14:55–88.
Robinson AG, Verbalis JG. Diabetes insipidus. Curr Ther Endocrinol Metab. 1997;6:1–7.
Robinson AG, Verbalis JG. Posterior pituitary. In: Melmed S, et al., editors. Williams textbook of endocrinology. 12th ed. Philadelphia: W.B. Saunders; 2011. p. 291–323.
Sands JM, Bichet DG. Nephrogenic diabetes insipidus. Ann Intern Med. 2006;144(3):186–94. Available from: PM:16461963.
SAMSCA (tolvaptan) Prescribing Information. Otsuka America Pharmaceutical, Inc., Princeton, N.J. 07US14L-0919A, Rev. 02,2014.
Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355(20):2099–112. Available from: PM:17105757.
Schwartz WB, Bennett S, Curelop S, Bartter FC. A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone. Am J Med. 1957;23:529–42.
Singer I, Rotenberg D. Demeclocycline-induced nephrogenic diabetes insipidus. In-vivo and in- vitro studies. Ann Intern Med. 1973;79(5):679–83. Available from: PM:4356453.
Sofroniew MV, Weindl A, Schrell U, Wetzstein R. Immunohistochemistry of vasopressin, oxytocin and neurophysin in the hypothalamus and extrahypothalamic regions of the human and primate brain. Acta Histochem Suppl. 1981;24:79–95. Available from: PM:6785843.
Soupart A, Penninckx R, Crenier L, Stenuit A, Perier O, Decaux G. Prevention of brain demyelination in rats after excessive correction of chronic hyponatremia by serum sodium lowering. Kidney Int. 1994;45:193–200.
Spasovski G, Vanholder R, Allolio B, Annane D, Ball S, Bichet D, Decaux G, Fenske W, Hoorn EJ, Ichai C, Joannidis M, Soupart A, Zietse R, Haller M, van der Veer S, Van BW, Nagler E. Clinical practice guideline on diagnosis and treatment of hyponatraemia. Nephrol Dial Transplant. 2014;29:i1. Available from: PM:24569496.
Steele A, Gowrishankar M, Abrahamson S, Mazer CD, Feldman RD, Halperin ML. Postoperative hyponatremia despite near-isotonic saline infusion: a phenomenon of desalination [see comments]. Ann Intern Med. 1997;126(1):20–5.
Sterns RH, Riggs JE, Schochet Jr SS. Osmotic demyelination syndrome following correction of hyponatremia. N Engl J Med. 1986;314:1535–42.
Sterns RH, Cappuccio JD, Silver SM, Cohen EP. Neurologic sequelae after treatment of severe hyponatremia: a multicenter perspective. J Am Soc Nephrol. 1994;4:1522–30.
Sterns RH, Nigwekar SU, Hix JK. The treatment of hyponatremia. Semin Nephrol. 2009;29(3):282–99. Available from: PM:19523575.
Swanson LW, Sawchenko PE. Paraventricular nucleus: a site for the integration of neuroendocrine and autonomic mechanisms. Neuroendocrinology. 1980;31(6):410–7. Available from: PM:6109264.
Thibonnier M, Conarty DM, Preston JA, Wilkins PL, Berti-Mattera LN, Mattera R. Molecular pharmacology of human vasopressin receptors. Adv Exp Med Biol. 1998;449:251–76. Available from: PM:10026814.
Thibonnier M, Coles P, Thibonnier A, Shoham M. The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists. Annu Rev Pharmacol Toxicol. 2001;41:175–202. Available from: PM:11264455.
Verbalis JG. Hyponatremia and hypo-osmolar disorders. In: Greenberg A, et al., editors. Primer on kidney diseases. 5th ed. Philadelphia: Saunders Elsevier; 2009. p. 52–9.
Verbalis JG. Brain volume regulation in response to changes in osmolality. Neuroscience. 2010;168(4):862–70. Available from: PM:20417691.
Verbalis JG. Disorders of water balance. In: Taal MW, et al., editors. Brenner & Rector’s the kidney. 9th ed. Philadelphia: Elsevier; 2012. p. 540–94.
Verbalis JG. The syndrome of inappropriate antidiuretic hormone secretion and other hypoosmolar disorders. In: Coffmna TM, et al., editors. Schrier’s diseases of the kidney. 9th ed. Philadelphia: Lippincott, Williams & Wilkins; 2013. p. 2012–54.
Verbalis JG. Posterior pituitary. In: Goldman L, Ausiello D, editors. Cecil medicine. 25th ed. Philadelphia: Saunders Elsevier; 2016a. p. 1494–9.
Verbalis JG. Disorders of water balance. In: Brenner B, editor. Brenner & Rector’s the kidney. 10th ed. Philadelphia: W.B. Saunders Elsevier; 2016b. p. 460–510.
Verbalis JG, Goldsmith SR, Greenberg A, Schrier RW, Sterns RH. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med. 2007;120(11 Suppl 1):S1–21. Available from: PM:17981159.
Zeltser D, Rosansky S, van Rensburg H, Verbalis JG, Smith N. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol. 2007;27(5):447–57. Available from: PM:17664863.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG
About this entry
Cite this entry
Verbalis, J.G. (2018). The Posterior Pituitary. In: Belfiore, A., LeRoith, D. (eds) Principles of Endocrinology and Hormone Action. Endocrinology. Springer, Cham. https://doi.org/10.1007/978-3-319-44675-2_13
Download citation
DOI: https://doi.org/10.1007/978-3-319-44675-2_13
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-44674-5
Online ISBN: 978-3-319-44675-2
eBook Packages: MedicineReference Module Medicine